The Most Consequential Question in Hormone Medicine
The relationship between hormone therapy and cardiovascular health is arguably the most clinically consequential and most actively researched question in the field. It’s also the question that most profoundly influenced (and arguably distorted) clinical practice following the 2002 Women’s Health Initiative study — and the one where evidence has evolved most significantly in the years since. Understanding the current evidence landscape is essential for both patients making treatment decisions and practitioners guiding them.
Testosterone and Cardiovascular Health in Men
The cardiovascular safety of testosterone replacement therapy in men has been the subject of intense debate, high-profile observational studies, and ultimately a landmark randomized controlled trial: the TRAVERSE trial. Published in 2023, TRAVERSE was a large, rigorous trial that found testosterone therapy did not increase the risk of major adverse cardiovascular events (MACE) — including heart attack, stroke, and cardiovascular death — in men with hypogonadism and elevated cardiovascular risk. The study provided the highest-quality evidence to date on TRT cardiovascular safety and largely resolved the uncertainty that had clouded this question for years.
Mechanistically, testosterone has multiple cardioprotective effects: it promotes vasodilation, reduces endothelial inflammation, improves lipid profiles (increasing HDL, reducing triglycerides), supports cardiac muscle function, improves insulin sensitivity (a major cardiovascular risk factor), and maintains beneficial body composition. Men with low testosterone have consistently higher rates of cardiovascular disease in observational data — raising the possibility that low testosterone is itself a cardiovascular risk factor, and that restoring it may be cardioprotective in properly selected patients.
Estrogen and Cardiovascular Health in Women
The cardiovascular effects of estrogen in women are profoundly influenced by timing — what researchers call the “timing hypothesis” or “critical window hypothesis.” When estrogen therapy is initiated within 10 years of menopause onset (or before age 60), it produces clear cardioprotective effects: improved lipid profiles (reduced LDL, increased HDL), enhanced endothelial function, reduced arterial inflammation, and potentially reduced coronary artery calcification progression. The DOPS (Danish Osteoporosis Prevention Study) trial found significantly lower cardiovascular events in women who received estrogen therapy in early menopause compared to controls.
When estrogen is initiated later — more than 10 years after menopause or in women over 60 — the cardiovascular picture is different, and potentially adverse. Atherosclerotic plaques that have developed in the estrogen-free years may respond unfavorably to estrogen’s vasodilatory effects, triggering plaque instability. This timing dependency explains why the WHI (which used older women averaging 63 years at enrollment) found different results than studies of younger, recently menopausal women.
The Route of Administration Matters
How hormones are administered significantly affects their cardiovascular risk profile. Oral estrogen undergoes first-pass liver metabolism, producing increased clotting factors, increased triglycerides, and increased C-reactive protein — all cardiovascular risk factors. Transdermal estrogen bypasses first-pass liver metabolism, avoiding these effects and showing a significantly more favorable cardiovascular and thrombotic risk profile in observational studies. Most current guidelines favor transdermal estrogen administration, particularly in women with cardiovascular risk factors or personal or family history of blood clots.
Similarly, the progestogen type matters. Medroxyprogesterone acetate (synthetic progestin) appears to attenuate estrogen’s cardioprotective effects and may have adverse cardiovascular effects of its own. Bioidentical micronized progesterone appears to preserve estrogen’s cardiovascular benefits and has a neutral or favorable cardiovascular profile — another reason why progestogen selection is a critical clinical decision in women’s hormone therapy.